Weight and Metabolic Outcomes in Naive HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

The use of integrase inhibitor-based antiretroviral therapy could be associated with worse weight and metabolic outcomes in patients with HIV infection.

Methods

PubMed, EMBASE, and Scopus were searched from inception to March 2022. We selected randomized controlled trials (RCTs) comparing integrase inhibitors with other antiretroviral classes (efavirenz-based or protease inhibitor-based therapies) in naïve HIV patients. Random effects meta-analysis was used to assess the effects of integrase inhibitors vs. controls on weight and lipid outcomes. Effects were described as mean differences (MD) and their 95% confidence intervals (CI). Certain pieces of evidence (CoE) were evaluated using the GRADE methodology.

Results

Six RCTs (n = 3521) were included, with pa

SUBMITTER: Valenzuela-Rodriguez G 

PROVIDER: S-EPMC10253862 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature